Last edition
News about Clinical Trials
BioNTech and OncoC4 Report Survival Benefit with Gotistobart in Squamous NSCLC
BioNTech and OncoC4 report updated phase 3 data showing gotistobart improved median Overall Survival (OS) to 18.5 months versus 10 months with chemotherapy in previously treated squamous NSCLC.
Clinical Trials | 14/09/2026 | By News Bureau
Adneuris Presents New Cebranopadol Data for Acute Pain Treatment
Adneuris presents new cebranopadol data showing lower abuse potential and positive phase 3 ALLEVIATE results for moderate-to-severe acute pain.
Clinical Trials | 14/09/2026 | By News Bureau
BioMarin Reports Positive Phase 3 VOXZOGO Results in Hypochondroplasia
BioMarin reports positive phase 3 VOXZOGO results in children with hypochondroplasia, showing significant improvements in growth measures and supporting Food and Drug Administration (FDA) supplemental New Drug Application (sNDA).
Clinical Trials | 11/09/2026 | By News Bureau
Imfinzi-Tarlatamab Combination Improves Overall Survival in Phase 3 ES-SCLC Trial
AstraZeneca and Amgen reported statistically significant improvements in overall and progression-free survival with Imfinzi plus tarlatamab versus Imfinzi alone in the Phase 3 DeLLphi-305 trial.
Clinical Trials | 10/09/2026 | By News Bureau
AstraZeneca Reports Positive Phase 3 Results for Tozorakimab in COPD
AstraZeneca’s Phase 3 OBERON and TITANIA trials showed that tozorakimab reduced moderate-to-severe COPD exacerbations across broad patient populations, including different blood eosinophil levels and smoking statuses.
Clinical Trials | 10/09/2026 | By News Bureau
Bayer Initiates Phase 2 Trial of Investigational GIRK4 Inhibitor for Atrial Fibrillation
Bayer has initiated a global Phase 2 trial of BAY 3670549, an investigational GIRK4 inhibitor being evaluated as a potential treatment for atrial fibrillation and rapid cardioversion.
Clinical Trials | 10/09/2026 | By News Bureau
Epicyt Pharma Reports Positive Phase 1/2a Results for BAFA in Post-Gastric Bypass Patients
Epicyt Pharma study shows statistically significant reduction in urinary calcium excretion and improvements in calcium homeostasis biomarkers, supporting planned Phase 2b development.
Clinical Trials | 09/09/2026 | By News Bureau
Ascletis Initiates US Phase 1 Study of Oral ASC36 for Obesity
Ascletis has initiated a US Phase 1 study of ASC36, an investigational oral amylin receptor peptide agonist developed using the company’s proprietary oral peptide delivery technology.
Clinical Trials | 09/09/2026 | By News Bureau
Bristol Myers Squibb’s arlo-cel demonstrated statistically significant and clinically meaningful responses in patients with quadruple-class exposed relapsed and refractory multiple myeloma.
Clinical Trials | 09/09/2026 | By News Bureau
Novartis Updates Phase 3 HARBOR Study of Del-desiran for DM1
Novartis reports del-desiran showed clinical activity in secondary endpoints and exploratory analyses in the phase 3 HARBOR study for DM1.
Clinical Trials | 09/09/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy